HEMISPHERX BIOPHARMA to Provide Update on Global Pandemic
Influenza Prevention / Treatment Initiatives
PHILADELPHIA, PA-July 20, 2009-Hemispherx Biopharma (NYSE AMEX: HEB) will provide an update on its Influenza research initiatives via teleconference on Wednesday, July 22, 2009, at 10:00 AM EDT. Initiatives to be discussed will include experimental programs planned or underway in Pacific Rim countries, Australia, South America and the United States. Background information may be sourced at Wall Street Journal, July 18/19, 2009, p. A3.
undefined undefined undefined undefined undefined undefinedHemispherx's Medical Director, CEO, and the Managing Director of the Sage Group, a health care consulting firm retained by Hemispherx, will participate. Investigational products and protocols to be discussed will include Hemispherx's Ampligen® (poly I: poly C12U), Alferon N (a natural cocktail of alpha 2 type interferons, FDA approved for treatment of refractory HPV) and Alferon LDO, an experimental formulation of Alferon-N for oral delivery.
To access the conference call:
U.S. Callers: 800-346-7359
International Callers: 973-528-0008
Conference Entry Code: 27781
I'm going to keep it till tomorrow, its a little risky because I'm pretty sure thestreet.com will release another article bashing it, but I feel that it can go into the high 3s maybe even 4s tomorrow before that happens.
i probably will to but have been riding this down for a while waiting on FDA. I would like to take some profits and re-buy before FDA announcement but there is risk in losing out if i sell. oh well, tomorrow = more ????????????
I think it is a good but risky strategy until the FDA announces it's decision on HEB's drug Ampligen. Hard to tell what is going to happen. Looks to just be an update for investor information on the company's strategies. Stock seems to be reacting positively to the news of the broadcast. If it goes to 4.00, I will sell what I have for a good profit. Set goals and stick to them. Hard to fight the inclination to be greedy...sigh.